Antibody Discovery Collaborative Center 

The Antibody Discovery Collaborative Center supports the development of human and murine monoclonal antibodies and other biologic modalities. Our goal is to promote basic and translational studies concentrated on the microbes responsible for catastrophic infectious diseases. The center operates an integrated platform for biologics discovery, expression, and characterization. To enable the generation of diverse lead sequences, we use both in vivo and in vitro methodologies to mine repertoires from animal immunization and synthetic antibody libraries. The center combines high-throughput screening and informatics to deliver diverse panels of binders against targets important for infectious disease research and beyond. 

Dr. Sunandan Banerjee obtained his PhD from University of Vermont in protein design and trained at the University of Toronto in synthetic antibody technologies. He has worked in biotech and big pharma and has over 10 years of progressive experience in therapeutic antibody development in both academia and industry. His primary interests lie in developing antibody discovery workflows, repertoire analysis to drive synthetic antibody library development and utilizing in vivo and in vitro technologies to drive therapeutic monoclonal antibody (mAb) discovery.